

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

# The cost-effectiveness of mammography-based female breast cancer screening in Canadian populations: a systematic review

Talha Tahir<sup>1</sup>, Melanie Mitsui Wong<sup>2</sup>, Rabia Tahir<sup>2</sup>, Michael Mitsui Wong<sup>3</sup>

<sup>1</sup>Michael G. DeGroot School of Medicine, McMaster University, Hamilton, Ontario, Canada.

<sup>2</sup>Bachelor of Health Sciences (Honours), McMaster University, Hamilton, Ontario, Canada.

<sup>3</sup>Bachelor of Life Sciences (Honours), McMaster University, Hamilton, Ontario, Canada.

\* Corresponding Author

Email: [talha.tahir@medportal.ca](mailto:talha.tahir@medportal.ca) (TT)

<sup>¶</sup>These authors contributed equally to this work.

---

<sup>1, 2, 3</sup> Address: McMaster University, 1280 Main Street West, Hamilton, Ontario, L8S 4L8

## 22 **Abstract**

### 23 **Introduction**

24 Mammography-based breast cancer screening is an important aspect of female breast  
25 cancer prevention within the Canadian healthcare system. The current literature on female breast  
26 cancer screening is largely focused on the health outcomes that result from screening. There is  
27 comparatively little data on the cost-effectiveness of the screening. Therefore, this paper sought  
28 to conduct a systematic review of the literature on the cost effectiveness of mammography-based  
29 breast cancer screening within female Canadian populations.

30

### 31 **Materials and methods**

32 A systematic review was performed in the PubMed database to identify all studies  
33 published within the last 10 years that addressed breast cancer screening and evaluate cost-  
34 effectiveness in a Canadian population.

35

### 36 **Results**

37 The search yielded five studies for inclusion, only three of which were applicable to  
38 average-risk Canadian women. The benefits of mortality reduction rose approximately linearly  
39 with costs, while costs were linearly dependent on the number of lifetime screens per woman.  
40 Moreover, triennial screening for average-risk women aged 50-69 years was found to be the  
41 most cost-effective in terms of cost per quality adjusted life year. The use of MRI in conjunction  
42 with mammography for women with the BRCA 1/2 mutation was found to be cost-effective  
43 while annual mammography-based screening for women with dense breasts was found to be  
44 cost-ineffective.

45

## 46 **Conclusion**

47           In spite of the growing interest to enhance breast cancer screening programs, analyses of  
48 the cost-effectiveness of mammography-based screening within Canadian populations are  
49 scarcely reported and have heterogeneous methodologies. The existing data suggests that  
50 Canada's current breast cancer screening policy to screen average-risk women aged 50-74,  
51 biennially or triennially is cost-effective. These findings could be of interest to health policy  
52 makers when making decisions regarding resource allocation; however, further studies in this  
53 field are required in order to make stronger recommendations regarding cost-effectiveness.

54

## 55 **Introduction**

56           Mammography-based female breast cancer screening is a modern staple of preventive  
57 healthcare [1]. It is administered in primary care facilities across Canada and the cost of the  
58 intervention is covered under Canada's public healthcare system [1]. While there is no direct  
59 policy associated with screening for breast cancer, the government of Canada makes  
60 recommendations to primary care physicians and the general public about screening protocols  
61 [1]. It is currently recommended that women between the ages of 50-74 years who are at  
62 average-risk of developing breast cancer are screened via mammography biennially or triennially  
63 [1]. There are established benefits to breast cancer screening, particularly because of its high  
64 prevalence and stage variable mortality [2]. In Canada, breast cancer represents 25% of all  
65 cancer diagnoses among women and 13% of all cancer diagnoses overall [2]. However, as a  
66 result of the implementation of screening practices and improved therapeutic interventions, the

67 mortality rate for female breast cancer has decreased by 44% since its peak in 1986 [2]. Since  
68 2010, more than 80% of all female breast cancer diagnoses have occurred at stage I and II, with  
69 only 5% being diagnosed at stage IV [2]. However, the statistics on mortality rates and disease  
70 incidence only tell the story of breast cancer from an epidemiological perspective. To truly  
71 understand how to create effective policy for organized breast cancer screening across Canada, it  
72 is necessary to investigate the cost-effectiveness of current screening protocols.

73  
74 Breast cancer screening recommendations are officially developed by the Canadian Task  
75 Force on Preventive Health Care (CTFPHC) [1]. The most recent breast cancer screening  
76 guidelines were released by the CTFPHC in 2018 [1]. While these guidelines and embedded  
77 recommendations incorporate a variety of factors, the emphasis is generally placed on patient  
78 costs and benefits. There is comparatively little exposure given to the financial costs of screening  
79 and false-positive scenarios. There is no analysis of cost-effectiveness within the current 2018  
80 Canadian breast cancer screening guidelines and there is only a cursory discussion of the  
81 economic implications of screening within the older 2011 guidelines. Moreover, the two articles  
82 that were cited for cost-effectiveness in the 2011 CTFPHC guidelines were studies conducted in  
83 South Korea and the United States [3]. To make informed policy decisions about breast cancer  
84 screening, it is imperative to analyze Canadian data on cost-effectiveness [1,3]. Therefore, this  
85 systematic review intends to evaluate the cost-effectiveness of female breast cancer screening  
86 policies in Canadian populations through an analysis of current literature. The objective of this  
87 paper is to declare Canada's current breast cancer screening policies as either cost-effective or  
88 ineffective and make recommendations that will increase cost-effectiveness in the future.

89

## 90 **Materials and methods**

91           A systematic literature review for all original studies that addressed breast cancer  
92 screening and/or those that attempted to evaluate cost-effectiveness was conducted in accordance  
93 with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)  
94 Statement guidelines for reporting [4,5] (S1 Table. Criteria for literature search methods and  
95 inclusion criteria were determined a priori. No review protocol exists for this study. A systematic  
96 search was performed within the PubMed electronic database for articles published in peer-  
97 reviewed journals, with a full text available in English. Only papers published within the last 10  
98 years were included to ensure the review was relevant to current breast cancer screening  
99 practices and treatment methods within Canada. In collaboration with an information specialist,  
100 we developed a search strategy tailored to the PubMed database using search terms such as “cost  
101 effectiveness”, “cost-benefit analysis”, “cost evaluation”, “Canada”, “screening”,  
102 “mammography”, “cancer”, “neoplasm”, “sarcoma”, and “breast” to identify studies  
103 investigating cost-effectiveness of mammogram screening in Canadian female populations (see  
104 S2 Table for the full search strategy).

105

### 106 **Eligibility Criteria**

107           Title and abstract screening were conducted in duplicate by TT and MMW to identify  
108 studies for full-text review. The search was limited to studies that featured data on the cost-  
109 effectiveness of mammography-based female breast cancer screening policies within a Canadian  
110 demographic. Only English full-text, original research articles published within the past 10 years  
111 were eligible for inclusion. Any discrepancies raised during the screening process were resolved  
112 through consensus by TT and MMW. Full texts of selected publications were retrieved and

113 assessed for eligibility by TT and MMW. Following full-text review, papers which contained  
114 original research related to breast cancer screening policies in Canada were included. Reference  
115 lists of included papers were also assessed to collect additional records and ensure that all  
116 relevant studies were captured.

117

## 118 **Data Extraction**

119 Should the publication have met all eligibility criteria, the study characteristics,  
120 parameters of the model used, incremental cost-effectiveness ratios, average total cost of  
121 screening, incremental cost per death averted, and number of women screened to avert one death,  
122 were independently extracted by TT and MMW. If eligible studies did not report data necessary  
123 for inclusion in the systematic review, efforts were made to contact the corresponding authors  
124 directly.

125

## 126 **Risk of Bias & Quality Assessment**


127 Risk of bias and study quality was assessed independently by TT and MMW using the  
128 Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Checklist (S3 Table)  
129 [6]. This 24-item evaluation tool includes guidelines for critically appraising the quality of  
130 reporting economic model characteristics, analytic methods, study parameters, incremental costs  
131 and outcomes, amongst others [6]. For each item, evidence of its description within each study  
132 was reported. Final risk of bias evaluations were determined through consensus and review of  
133 source documents.

134

## 135 Results

136 This search identified a total of 248 citations. After title and abstract screening, 29  
137 articles were selected to undergo full text review. This initial round of screening did not apply  
138 the recency requirement of 10 years mentioned previously. Upon applying this recency  
139 requirement during the examination of full text articles, 5 papers were accepted and included in  
140 the systematic review (Fig 1). The characteristics of included articles are presented in Table 1.  
141 Please refer to S4 Table in the supplementary repository to view the articles excluded by full text  
142 screening and their reasons for exclusion.

143 **Fig 1. PRISMA diagram of literature review process for PubMed Search and Screening.**



144

145 **Table 1. Characteristics and findings of included studies.**

| Study Authors        | Year | Findings  |
|----------------------|------|---|
| Pataky et al. [7]    | 2013 | Annual mammography plus MRI screening resulted in an ICER of \$50,900/QALY compared to annual mammogram screening alone.  |
| Pataky et al. [8]    | 2014 | Annual screening resulted in an additional 0.0014 QALYs compared to screening once every 2 years.   |
| Gocgun et al. [9]    | 2015 | Screening women aged 50-69 years once every 5 years is the most optimal with regards to cost per life saved. Annual mammogram screening is not cost-effective.  |
| Mittmann et al. [10] | 2015 | Screening women aged 50-69 once every three years is the most cost-effective at \$83,070 per life year gained and \$94,762 per QALY.  |
| Mittmann et al. [11] | 2018 | Annual screening per 1000 women costs the healthcare system \$7.4-10.7 million compared to a no-screening scenario, which would cost the system \$3.0 million per 1000 women. All screening programs increased life years gained and QALYs. |

146

147

The Consolidated Health Economic Evaluation Reporting Standards (CHEERS)

148

Checklist was applied to the 5 studies included in this review [6]. Upon evaluation, every article

149

fulfilled most of the criteria on the checklist (S1 Table) and thus were deemed to be of good

150

quality. All studies clearly presented well-defined research questions, characterized the study

151

population, and provided justifications for the specific type of analytical model used. A notable

152

difference between the articles was the presence of confidence intervals. The 2015 and 2018

153

papers by Mittman et al. did not contain confidence intervals or any other metric expressing

154

uncertainty about their point estimates [10,11]. However, given that the papers incorporated a

155

variety of cost, sensitivity, and incidence data to generate their models, this may explain the

156

omission of confidence intervals within these studies.



157 This review takes a qualitative approach at evaluating the included studies. A meta-  
158 analysis could not be conducted due to the significant heterogeneity between the studies. In  
159 addition, the use of different models with varying input parameters, discounting rates, time  
160 horizons, and costs made it infeasible to statistically combine the studies.

161 The included studies varied in the populations studied, which were subdivided into two  
162 categories: those presenting a cost-effectiveness analysis for screening women at an average-risk  
163 for breast cancer, and those assessing cost-effectiveness for high-risk women. Three articles  
164 calculated the cost-effectiveness for screening average-risk women, Mittman et al 2015, Mittman  
165 et al 2018, and Gocgun et al 2015 (Table 2) [9–11].

166 **Table 2. Characteristics of studies assessing cost-effectiveness for screening average-risk**  
167 **women.**

| <b>Study Authors (year)</b> | <b>Primary Outcome</b>             | <b>Screening Intervention</b> | <b>Time Horizon</b> | <b>Costs</b>  |
|-----------------------------|------------------------------------|-------------------------------|---------------------|---|
| Gocgun et al. (2015) [9]    | Incremental cost per death averted | Film-based mammography        | 20 years            | 2015 Canadian dollars using Ontario-based costs for screening and treatment |
| Mittmann et al. (2015) [10] | Incremental cost per QALY          | Digital mammography           | Lifetime            | 2012 Canadian dollars using Ontario-based costs for screening and treatment |
| Mittmann et al. (2018) [11] | Incremental cost per QALY          | Digital mammography           | Lifetime            | 2012 Canadian dollars using Ontario-based costs for screening and treatment |

168

169 Both papers by Mittman et al. used the same University of Wisconsin Breast Cancer  
170 Epidemiology Simulation model. but addressed the topic from different perspectives [10,11].  
171 The 2018 Mittman et al. paper considered cost-effectiveness from a single payer public  
172 healthcare system perspective, [11] whereas the 2015 paper by the same lead author considered  
173 cost-effectiveness from a societal perspective [10]. Both studies also used digital mammography  
174 as the screening intervention, expressed their costs in 2012 Canadian dollars using Ontario-based  
175 costs (Ontario Health Insurance Plan (OHIP)) for screening and treatment, and employed a  
176 lifetime horizon for cost calculation. The homogenous methodologies applied across these two  
177 papers thus made their respective estimates easy to compare.

178 The two Mittman papers concluded that the benefits of mortality reduction rose  
179 approximately linearly with costs, while costs were linearly dependent on the number of lifetime  
180 screens per woman. Then, the decision to screen is largely based on willingness to pay. To  
181 compare cost-effectiveness, an analysis of the incremental cost-effectiveness ratios (ICERs) of  
182 the two Mittman et al. studies was performed (Table 3).

183 **Table 3. Cost-effectiveness of screening scenarios in Mittman et al. 2015 and Mittman et al.**  
184 **2018.** [10,11]

|                                 | <b>Triennial 50-69 years</b> | <b>Biennial 50-69 years</b> | <b>Annual 50-69 years</b> |
|---------------------------------|------------------------------|-----------------------------|---------------------------|
| <b>Mittman et al. 2015</b> [10] | \$94,762/QALY                | \$97,006/QALY               | \$159,858/QALY            |
| <b>Mittman et al. 2018</b> [11] | \$36,918/QALY                | \$38,142/QALY               | \$65,944/QALY             |

185

186           The 2015 Mittman et al. study had far higher ICERs due to its inclusion of costs to  
187 society, particularly loss in productivity [10]. Only 3 screening scenarios are examined in Table  
188 2, as the 50-69 years age group closely approximates the current Canadian recommendation to  
189 screen average-risk women between 50-74 years of age. In both studies, the simulations with the  
190 50-74 years age group were weakly dominated by the 50-69 years age group. Therefore, these  
191 studies provide support to the argument that average-risk women aged 70-74 years should not be  
192 screened using digital mammography.

193           The third study that examined cost-effectiveness for average-risk women was conducted  
194 by Gocgun et al. [9]. This study cannot be directly compared against the Mittman et al. studies  
195 because it did not calculate incremental cost per quality adjusted life year (QALY), instead  
196 opting to calculate incremental cost per death averted. Moreover, unlike the two Mittman et al.  
197 studies, Gocgun et al. did not use a lifetime horizon; instead, costs were evaluated over a horizon  
198 of 20 years. Gocgun et al. used data from the Canadian National Breast Cancer Screening Study  
199 to create and validate their model [9]. It should be noted that the data used to create this model  
200 was generated using film-based mammography, a screening technique that has since been  
201 replaced with digital mammography. The increased sensitivity of digital mammography may  
202 have resulted in more cost-effective outcomes. Ontario (OHIP) data expressed in 2015 Canadian  
203 dollars was used to input costs of screening and treatment scenarios [9].

204           Gocgun et al. (2015) concluded that more aggressive screening scenarios generate greater  
205 health benefits but at an increased cost (Table 4) [9]. Screening average-risk women aged 50-69  
206 years every 5 years was found to have the lowest incremental costs, but the highest number of  
207 women screened to avert one death. Biennial screening for average-risk women between 50-69

208 years had the most favorable combination of incremental cost per death averted and number of  
209 women screened to avert one death. Similar to Mittman et al., Gocgun et al. found a sharp  
210 increase in cost per utility, or in this case, cost per death averted when comparing biennial or  
211 triennial screening to annual screening [9].

212 **Table 4. Cost-effectiveness of select screening scenarios from Gocgun et al. 2015. [9]**

|  | <b>Triennial 50-69 years</b> | <b>Biennial 50-69 years</b> | <b>Annual 50-69 years</b> |
|--|------------------------------|-----------------------------|---------------------------|
| <b>Average total cost (screening, diagnosis and treatment costs)</b> | \$16,298,486                 | \$18,414,393                | \$24,091,226              |
| <b>Incremental cost per death averted</b>                            | \$626,973                    | \$654,940                   | \$981,265                 |
| <b>Number of women screened to avert one death</b>                   | 1,332                        | 960                         | 785                       |

213

214 The remaining 2013 and 2014 studies by Pataky et al. included in this review focused on  
215 populations at high-risk for breast cancer (Table 5) [7,8]. Both studies constructed their  
216 Markovian model based on breast cancer incidence, treatment, and screening costs in British  
217 Columbia using a lifetime horizon for the calculation of costs. The 2013 study by Pataky et al.  
218 examined cost-effectiveness of using Magnetic Resonance Imaging (MRI) in conjunction with  
219 mammography for women carrying the BRCA1/2 mutation, expressing costs in 2008 Canadian  
220 dollars [7]. Women with the BRCA1/2 mutation are at a higher risk of developing breast cancer,  
221 therefore, they may benefit from the higher sensitivity of the MRI [12]. Pataky et al. (2013)

222 found an ICER of \$50,911/QALY for using MRI in conjunction with mammography instead of  
223 using mammography alone [7]. At a willingness to pay of \$100,000/QALY, the use of MRI  
224 screening is cost-effective 85.6% of the time. However, Pataky et al. found the model to be  
225 highly dependent on the cost of an MRI scan, which may change the applicability of the result in  
226 locations where an MRI scan is more expensive [7].

227         The 2014 study by Pataky et al. investigated the cost-effectiveness of annual vs. biennial  
228 mammography screening for women with dense breasts, expressing costs in 2007 Canadian  
229 dollars [8]. The sensitivity of mammography screening was significantly lower in women with  
230 dense breasts, consequently making them more likely to be diagnosed with interval cancers [13].  
231 The study found that screening breast cancer in women with dense breasts annually instead of  
232 biennially has an ICER of \$565,912/QALY [8]. The extremely high ICER coupled with the fact  
233 that only 43.4% of the simulations showed annual screening to reduce QALYs relative to  
234 biennial screening suggest the cost-ineffectiveness of this strategy [8]. Moreover, the sensitivity  
235 data used in this study was for film-based mammography instead of digital mammography,  
236 making it difficult to judge cost-effectiveness in a healthcare environment dominated by digital  
237 mammography. Based on this study, annual breast cancer screening for women with dense  
238 breasts can effectively be considered cost-ineffective until further research proves otherwise [8].

239

240 **Table 2. Characteristics of studies assessing cost-effectiveness for screening high-risk**  
241 **women**

| <b>Study Authors (year)</b> | <b>Primary Outcome</b>    | <b>Screening Intervention</b>                              | <b>Time Horizon</b> | <b>Costs</b>   |
|-----------------------------|---------------------------|--|---------------------|--|
| Pataky et al. (2013) [7]    | Incremental cost per QALY | Magnetic resonance imaging in conjunction with mammography | Lifetime            | 2008 Canadian dollars using British Columbia-based costs for screening and treatment |
| Pataky et al. (2014) [8]    | Incremental cost per QALY | Film-based mammography                                     | Lifetime            | 2007 Canadian dollars using British Columbia-based costs for screening and treatment |

242

## 243 **Discussion**

244 To the best of our knowledge, this is the first systematic review that assesses the cost  
245 effectiveness of mammography-based breast cancer screening within Canadian female  
246 populations. The results of the 5 studies included in this review ultimately suggest that  
247 aggressive screening strategies incur higher costs, but they also provide more health benefits.  
248 The optimal strategy for any given situation is decided largely by willingness to pay. However, a  
249 public healthcare system like Canada must make concrete decisions on which screening practices  
250 to implement based on clinical and cost-effectiveness. To make such a decision, it is necessary to  
251 understand the thresholds for cost-effectiveness within the field of oncology.

252 According to a 2010 paper that evaluated the attitudes of US and Canadian physicians on  
253 cost-effectiveness, the majority of oncologists in both Canada and the United States see  
254 \$100,000/life-year as the threshold for cost-effective oncology treatments [14]. Traditionally,

255 when examining healthcare interventions, the threshold of \$50,000/QALY (USD) has been cited  
256 [15]. However, in recent literature, the trend has been to use a threshold of \$100,000/QALY with  
257 the World Health Organization and many economists arguing that thresholds of anywhere from  
258 \$110,000 to \$160,000 per QALY should be used in a population like the United States, given  
259 median household income and other factors [15]. If one were to extrapolate these results to  
260 Canada, it seems that at the very minimum a value of \$100,000/QALY should be used when  
261 evaluating the cost-effectiveness of breast cancer screening procedures.

262         Having made this assumption, we find that the estimates given by both the 2018 and 2015  
263 Mittman et al. studies for biennial and triennial screening of average-risk women between the  
264 ages of 50-69 years fall below the threshold of \$100,000/QALY [10,11]. It seems that even with  
265 the inclusion of societal costs such as loss in productivity, biennial and triennial screening of  
266 women aged 50-69 years is cost-effective. The results of the study by Gocgun et al. cannot be  
267 analyzed by the metric of cost-effectiveness we have used above, as the study did not integrate  
268 QALYs in its incremental cost-effectiveness ratios. Moreover, Gocgun et al.'s study, more than  
269 any other in this review, suffered from a poorly constructed model that was forced to make  
270 multiple simplifying assumptions due to data scarcity. For example, due to data scarcity, Gocgun  
271 et al. assumed the stage distribution of clinically presenting cancer for the 60-69 age group to be  
272 the same as that for the 50-59 age groups [9]. As a result, we will exclude Gocgun et al. results in  
273 making a decision about the cost-effectiveness of Canada's current breast cancer screening  
274 policies.

275         The 2014 study by Pataky et al. on the cost-effectiveness of annual vs. biennial  
276 mammography breast cancer screening for women with dense breasts found an ICER of

277 \$565,912/QALY [8]. The high ICER and the variation seen in the simulations for annual versus  
278 biennial breast cancer screening for women with dense breasts leaves us uncertain about its cost-  
279 effectiveness. Lastly, the 2013 Pataky et al. study looking at using MRI screening in conjunction  
280 with mammography on women carrying the BRCA1/2 mutation found an ICER of  
281 \$50,911/QALY as compared to mammography screening alone [7]. This is well below our cost-  
282 effectiveness threshold of \$100,000/QALY and suggests that using MRI in conjunction with  
283 mammography is indeed cost-effective for that specific population of women.

284         The consensus seems to be that the current breast cancer screening policies of Canada, to  
285 screen average-risk women aged 50-74 years biennially or triennially, are cost-effective.  
286 However, the results of the above studies suggest that it is cost-ineffective to screen women with  
287 dense breasts annually and that it is cost-effective for women with the BRCA1/2 mutation to be  
288 given the option of using MRI in conjunction with digital mammography.

289         The results of the review must be tempered by the heterogeneity and limitations of the  
290 constitutive studies. The included papers used different models that were validated with different  
291 reference data, utilized different time horizons, and conducted different numbers of simulations.  
292 Moreover, the cost-effectiveness of breast cancer screening programs tends to be highly sensitive  
293 to the discounting rate, as many of the costs are accrued near the beginning of the program while  
294 the benefits are reaped near the end. Every study used a different discounting rate with 1.5% as  
295 the lowest and 5% as the highest. The methodological differences between studies mean that the  
296 results of this review must be interpreted with caution and that it is difficult to make firm  
297 statements about the cost-effectiveness of breast cancer screening in Canada.

298



299           Despite the heavy focus on optimizing breast cancer screening protocols, there is a  
300   scarcity of literature available on the cost-effectiveness of breast cancer screening within  
301   Canadian populations. Further studies are required to be able to make stronger recommendations  
302   regarding cost-effectiveness, which will prove critical in making decisions regarding resource  
303   allocation. The concerns presented in this review could serve as a basis for consideration by  
304   health policy makers, who must consider cost as a major factor when evaluating mammogram  
305   screening programs.

306

307

## 308 **References**

- 309 1. Klarenbach S, Sims-Jones N, Lewin G, Singh H, Thériault G, Tonelli M, et al.  
310 Recommendations on screening for breast cancer in women aged 40-74 years who are not  
311 at increased risk for breast cancer. *CMAJ*. 2018;190: E1441–E1451.  
312 doi:10.1503/cmaj.180463
- 313 2. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer  
314 Statistics 2018. Can Cancer Soc. 2018. doi:0835-2976
- 315 3. The Canadian Task Force on Preventative Health Care. Recommendations on screening  
316 for breast cancer in average-risk women aged 40-74 years. *CMAJ*. 2011;183: 1991–2001.  
317 doi:10.1503/cmaj.110334
- 318 4. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The  
319 PRISMA statement for reporting systematic reviews and meta-analyses of studies that  
320 evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol*.  
321 2009;62: e1–e34. doi:10.1016/j.jclinepi.2009.06.006
- 322 5. Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred  
323 reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS*  
324 *Medicine*. 2009. doi:10.1371/journal.pmed.1000097
- 325 6. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al.  
326 Consolidated health economic evaluation reporting standards (CHEERS)-explanation and  
327 elaboration: A report of the ISPOR health economic evaluation publication guidelines  
328 good reporting practices task force. *Value Heal*. 2013;346: f1049.  
329 doi:10.1016/j.jval.2013.02.002
- 330 7. Pataky R, Armstrong L, Chia S, Coldman AJ, Kim-Sing C, McGillivray B, et al. Cost-

- 331 effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers. *BMC*  
332 *Cancer*. 2013;13: 339. doi:10.1186/1471-2407-13-339
- 333 8. Pataky R, Ismail Z, Coldman AJ, Elwood M, Gelmon K, Hedden L, et al. Cost-  
334 effectiveness of annual versus biennial screening mammography for women with high  
335 mammographic breast density. *J Med Screen*. 2014;21: 180–188.  
336 doi:10.1177/0969141314549758
- 337 9. Gocgun Y, Banjevic D, Taghipour S, Montgomery N, Harvey BJ, Jardine AKS, et al.  
338 Cost-effectiveness of breast cancer screening policies using simulation. *Breast*. 2015;24:  
339 440–448. doi:10.1016/j.breast.2015.03.012
- 340 10. Mittmann N, Stout NK, Lee P, Tosteson ANA, Trentham-Dietz A, Alagoz O, et al. Total  
341 cost-effectiveness of mammography screening strategies. *Health Reports*. 2015;26: 16–25.  
342 doi:10.1001/jama.274.11.881
- 343 11. Mittmann N, Stout NK, Tosteson ANA, Trentham-Dietz A, Alagoz O, Yaffe MJ. Cost-  
344 effectiveness of mammography from a publicly funded health care system perspective. *C*  
345 *Open*. 2018;6: E77-86. doi:10.9778/cmajo.20170106
- 346 12. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et  
347 al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2  
348 mutation carriers. *JAMA - J Am Med Assoc*. 2017;317: 2402–2416.  
349 doi:10.1001/jama.2017.7112
- 350 13. Harvey JA, Bovbjerg VE. Quantitative Assessment of Mammographic Breast Density:  
351 Relationship with Breast Cancer Risk. *Radiology*. 2004;230: 29–41.  
352 doi:10.1148/radiol.2301020870
- 353 14. Berry SR, Bell CM, Ubel PA, Evans WK, Nadler E, Strevel EL, et al. Continental divide?

- 354           The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health  
355           policies associated with new cancer drugs. *J Clin Oncol.* 2010;28: 4149–4153.  
356           doi:10.1200/JCO.2010.29.1625
- 357 15.   Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness - The curious  
358           resilience of the \$50,000-per-QALY threshold. *N Engl J Med.* 2014;371: 796–797.  
359           doi:10.1056/NEJMp1405158

360

## 361 **Supporting information**

362 **S1 Table. PRISMA Checklist.**

363 **S2 Table. Search strategy.**

364 **S3 Table. CHEERS Checklist for Included Articles.**

365 **S4 Table. Papers excluded from full text review along with reasons for exclusion.**